Slide 1: Immuron CEO to present at Coffee Microcaps
Immuron CEO, Steven Lydeamore to present at Coffee Microcaps Melbourne, Australia, March 14 , 2024 : Immuron Limited (ASX : IMC ; NASDAQ : IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presentin
Slide 2: Immuron Platform Technology
Immuron Platform Technology Immuron’s proprietary technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper - immune bovine colostrum . Immuron has the capability of producing highly specific immunoglobulins to any enteric pathogen and our products are orally active . Bov
Slide 3: Investor Presentation - Coffee Microcaps, 14 March 2024
1 1 INVESTOR PRESENTATION CO F F EE M I C RO C APS 14 MARCH 2024 S teven Lydeamore - CEO NASDAQ: IMRN ASX: IMC For personal use only
Slide 4: Forward-looking statements
2 Certain statements made in this presentation are forward - looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “ intends,” “ plans,” “ believes,” “ seeks,” “estimates,” “guidance” and s imilar expressions are intend
Slide 5: Revenue Generating with Strong Pipeline
3 REVENUE GENERATING WITH STRONG PIPELINE Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases Financial Snapshot 7 - Mar - 24 (FYTD) 30 - Jun - 23 (FY) 22
Slide 6: Revenue Generating with Strong Pipeline: Pipeline Snapshot
4 REVENUE GENERATING WITH STRONG PIPELINE Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases Pipeline Snapshot 7 - Mar - 24 30 - Jun - 23 Topline results
Slide 7: Technology Platform for Gut Mediated Diseases
TECHNOLOGY PLATFORM FOR GUT MEDIATED DISEASES Bovine colostrum is the first milk of cows after calving. It is rich in immunoglobulins, lactoferrin, lysozyme, lactoperoxidase, growth factors and bioactive peptides. Colostrum has higher levels of protein, fat, vitamins, and minerals when compared to m
Slide 8: Strong Pipeline with Near Term Milestones
6 6 STRONG PIPELINE WITH NEAR TERM MILESTONES 6 Market Phase III Phase II Phase I Indication Compound or brand name Traveler’s Diarrhea ETEC challenge IMM - 124E Travelan® Clostridioides difficile Infection & Recurrence IMM - 529 Market Phase III Phase II Phase I Partner Compound or brand name ersit
Slide 9: Valuable Sales Potential for Pipeline Products
7 VALUABLE SALES POTENTIAL FOR PIPELINE PRODUCTS › Immuron’s development of IMM - 124E (hyperimmune bovine colostrum) as a prescription medication has the potential to address this unmet need › Primary care physicians (PCP)s impressed with clinical efficacy endpoint targets demonstrating > 80% prote
Slide 10: Near Term Milestones Anticipated to Drive Value
8 NEAR TERM MILESTONES ANTICIPATED TO DRIVE VALUE 2H 2024 Completed ; 1. Investigational New Drug; 2. Enterotoxigenic E.coli ; 3. controlled human infection model; 4. Institutional Review Board; 5. Naval Medical Research Command; 6. Uniformed Health Services University of the Health Sciences; 7. Clo
Slide 11: Billion Dollar Market - High Unmet Need
9 IMM - 124E BILLION DOLLAR MARKET - HIGH UNMET NEED Industry tailwinds Travel picking up significantly following COVID lockdowns Billion Dollar Market Traveller’s diarrhoea treatment market is large and growing at a CAGR of ~7% Frequent Symptoms 30% - 70% of travelers experience traveller’s diarrho
Slide 12: Positive Results Support Travelan Progress to Phase 3
10 • Positive Results Support Travelan® progress to Phase 3 • IMM - 124E Phase 2 • Healthy volunteers were recruited and randomized to receive a single daily oral dose of 1200 mg of Travelan® or placebo. Dosing commenced 2 days prior to challenge with ETEC strain H10407 and continued for 7 days. • 6
Slide 13: Phase Strategy
11 IMM - 124E PHASE 3 STRATEGY • Trial duration ~ 2 years • End of Phase 3 FDA meeting • BLA 3 submission • Initiate Phase 3 • Phase 3 FDA meeting • Clinical Study Report • End of Phase 2 FDA meeting • Phase 1 clinical study (Baltimore, 1996) • Phase 2 clinical study (Poland, 2000) • FDA 1 IND 2 app
Slide 14: World First Triple Mechanism of Action for CDI
1 2 12 WORLD FIRST TRIPLE MECHANISM OF ACTION FOR CDI 12 IMM - 529 IMM - 529 will be indicated for the treatment of recurrent C. difficile infection Indication / Target Population • Novel antibody - containing therapeutic which neutralizes C. difficile but does not impact the microbiome • Targets no
Slide 15: Scientific References
1 3 13 SCIENTIFIC REFERENCES Travelan® (IMM - 124E) Scandinavian Journal of Gastroenterology, 46:7 - 8, 862 - 868, DOI: 10.3109/00365521.2011.574726 Travelan® has been shown to reduce both the incidence and severity of ETEC - induced diarrhea in up to 90% of volunteers Military Health System Researc
Slide 16: Contact Information
14 EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172 STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: For personal use only